Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin
K Mori, O Hiraoka, M Ikeda, Y Ariumi, A Hiramoto… - Hepatology, 2013 - journals.lww.com
Ribavirin (RBV) is often used in conjunction with interferon-based therapy for patients with
chronic hepatitis C. There is a drastic difference in the anti–hepatitis C virus (HCV) activity of
RBV between the HuH-7-derived assay system, OR6, possessing the RBV-resistant
phenotype (50% effective concentration [EC 50]:> 100 μM) and the recently discovered Li23-
derived assay system, ORL8, possessing the RBV-sensitive phenotype (EC 50: 8 μM;
clinically achievable concentration). This is because the anti-HCV activity of RBV was …
chronic hepatitis C. There is a drastic difference in the anti–hepatitis C virus (HCV) activity of
RBV between the HuH-7-derived assay system, OR6, possessing the RBV-resistant
phenotype (50% effective concentration [EC 50]:> 100 μM) and the recently discovered Li23-
derived assay system, ORL8, possessing the RBV-sensitive phenotype (EC 50: 8 μM;
clinically achievable concentration). This is because the anti-HCV activity of RBV was …